Anti-PD-1 More Effective With Normal Vitamin D Levels in Melanoma
MONDAY, April 24, 2023 -- For patients with advanced melanoma, treatment with anti-programmed cell death 1 (anti-PD-1) results in improved response rate and longer progression-free survival for those with normal vitamin D levels, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 24, 2023 Category: Pharmaceuticals Source Type: news
Pembrolizumab Monotherapy Effective for Rare Melanoma Pembrolizumab Monotherapy Effective for Rare Melanoma
Pembrolizumab led to a dramatic overall response rate among patients with unresectable desmoplastic melanoma.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 19, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
AACR: mRNA-4157 Plus Pembrolizumab Beneficial in Melanoma
MONDAY, April 17, 2023 -- For patients with completely resected, high-risk cutaneous melanoma, the novel mRNA-based cancer vaccine (mRNA-4157) combined with pembrolizumab results in improved recurrence-free survival (RFS) compared with pembrolizumab... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 17, 2023 Category: Pharmaceuticals Source Type: news
Experimental cancer vaccine combined with immunotherapy delayed return of melanoma, Moderna and Merck say
New data from a trial of an investigational mRNA vaccine shows that it reduced the risk of recurrence of the serious skin cancer melanoma when combined with immunotherapy, according to drugmakers Moderna and Merck. (Source: CNN.com - Health)
Source: CNN.com - Health - April 17, 2023 Category: Consumer Health News Source Type: news
Experimental cancer vaccine combined with immunotherapy delayed return of melanoma, Moderna and Merck say
New data from a trial of an investigational mRNA vaccine shows that it reduced the risk of recurrence of the serious skin cancer melanoma when combined with immunotherapy, according to drugmakers Moderna and Merck. In a trial of 157 people who had had surgery to treat melanoma, 78.6% of those who…#merck #keytruda #kyleholen #mrna4157v940 (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2023 Category: Consumer Health News Source Type: news
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), …
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection Results from the Phase 2b KEYNOTE-942 trial selected for AACR press program Companies…#keytruda #cambridge #rahway #njaccesswire #rna #merck #msd #mrna4157p201 #mrna4157 #rfs (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2023 Category: Consumer Health News Source Type: news
Responses to PD-1 Blockade Approach 90% in Rare Melanoma
(MedPage Today) -- ORLANDO -- Exceedingly high response rates were seen with pembrolizumab (Keytruda) in patients with unresectable metastatic desmoplastic melanoma, according to results from the SWOG S1512 phase II trial presented here.
Among... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - April 17, 2023 Category: Dermatology Source Type: news
Moderna's cancer vaccine may be a 'major breakthrough', scientists say
A phase two clinical trial found the shot combined with immunotherapy drug Merck slashed the risk of melanoma returning by 44 percent compared to using the drug alone. (Source: the Mail online | Health)
Source: the Mail online | Health - April 17, 2023 Category: Consumer Health News Source Type: news
' Exciting' Results for Cancer Vaccine Plus Pembro in Melanoma'Exciting' Results for Cancer Vaccine Plus Pembro in Melanoma
Combining Moderna ' s patient-specific mRNA-based cancer vaccine with pembrolizumab may prolong recurrence-free survival in patients with high-risk melanoma vs pembrolizumab alone, new data show.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Moderna and Merck prepare for PhIII trial of cancer vaccine, and an expansion to lung cancer: #AACR23
ORLANDO – Moderna and Merck plan to launch a Phase III study this year for their personalized cancer vaccine in melanoma, and have revealed more details from a Phase IIb test that earlier this year renewed excitement about the use of vaccines in fighting tumors. The news comes just a month after…#orlando #merck #melanoma #moderna #stephenhoge #ericrubin (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2023 Category: Consumer Health News Source Type: news
Therapeutic Cancer Vaccine Boosts Survival for People Battling Advanced Melanoma
MONDAY, April 17, 2023 -- An experimental vaccine whipped up to specifically target a melanoma patient ’s tumor cells significantly reduces the likelihood of the cancer recurring, early clinical trial data show.
Each dose of the vaccine, called... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 17, 2023 Category: General Medicine Source Type: news
Health Highlights: April 17, 2023
Therapeutic cancer vaccine boosts survival for people battling advanced melanoma. Each dose of the vaccine is crafted based on the unique genetics of the patient ’s cancer cells, and teaches the immune system to find and kill the cells. Read... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 17, 2023 Category: General Medicine Source Type: news
Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma
(MedPage Today) -- ORLANDO -- Adding a personalized cancer vaccine to anti-PD-1 immunotherapy for resectable melanoma led to a 44% improvement in recurrence-free survival (RFS) versus immunotherapy alone, according to a study reported here.... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - April 17, 2023 Category: Dermatology Source Type: news
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), …
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection Results from the Phase 2b KEYNOTE-942 trial selected for AACR press program Companies…#keytruda #cambridge #rahway #njaccesswire #rna #merck #msd #mrna4157p201 #mrna4157 #rfs (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2023 Category: Consumer Health News Source Type: news
Skin cancer vaccine halved the risk of relapse in melanoma patients, research finds
Research demonstrates that an mRNA vaccine can successfully supplement treatment against cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - April 16, 2023 Category: Consumer Health News Source Type: news